FLERIE (FLERIE) News
Follow FLERIE (FLERIE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Nanologica Names Mark Quick CEO, Plans SEK 110.5M Rights Issue
Flerie said its portfolio company Nanologica appointed Mark Quick as CEO and announced a partially guaranteed rights issue of approximately SEK 110.5 million to support its updated growth strategy.
EQUITY | Oct 23, 2026, 09:10 AM UTC
M
Flerie Merger With Biosergen Approved by Sweden’s Bolagsverket
The merger is expected to register on Oct. 23, 2026. Biosergen will be delisted Oct. 22; holders as of Oct. 26 are to receive 1 Flerie share per 31 Biosergen shares, around Oct. 28.
MNA | Oct 16, 2026, 02:00 PM UTC
L
Flerie AB (publ) (FLERIE) Notes FDA Approval for Egetis Drug
Flerie said its portfolio company Egetis Therapeutics received FDA approval for EMCITATE (tiratricol) for MCT8 deficiency and was granted a Rare Pediatric Disease Priority Review Voucher.Material DetailsContext by AI Ana
REGULATION | Sep 29, 2026, 09:51 AM UTC
M
Nasdaq approves Biosergen delisting application
EQUITY | Sep 17, 2026, 02:32 PM UTC
L
Flerie AB NAV for 31 August 2026: SEK 3,342m
Flerie AB reported Net Asset Value of SEK 3,342 million as of 31 August 2026, with NAV per share at SEK 38.54. Return on NAV per share over the month was -1.8%.
EQUITY | Sep 02, 2026, 06:00 AM UTC